Phio Pharmaceuticals Corp
PHIO2.350USD
+0.020+0.86%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
11.23MCap. mercado
PérdidaP/E TTM
Más Datos de Phio Pharmaceuticals Corp Compañía
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
Información de la empresa
Símbolo de cotizaciónPHIO
Nombre de la empresaPhio Pharmaceuticals Corp
Fecha de salida a bolsaMay 10, 2012
Director ejecutivoMr. Robert J. Bitterman
Número de empleados5
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 10
Dirección411 Swedeland Road
CiudadKING OF PRUSSIA
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal19406
Teléfono15087673861
Sitio Webhttps://phiopharma.com/
Símbolo de cotizaciónPHIO
Fecha de salida a bolsaMay 10, 2012
Director ejecutivoMr. Robert J. Bitterman
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Robert J. Bitterman
Mr. Robert J. Bitterman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
27.15K
+168.32%
Mr. Robert L. Ferrara, CPA
Mr. Robert L. Ferrara, CPA
Lead Independent Director
Lead Independent Director
15.67K
+176.49%
Dr. Curtis A. Lockshin, Ph.D.
Dr. Curtis A. Lockshin, Ph.D.
Independent Director
Independent Director
356.00
--
Mr. David H. Deming
Mr. David H. Deming
Independent Director
Independent Director
--
--
Ms. Patricia A. (Pat) Bradford
Ms. Patricia A. (Pat) Bradford
Independent Director
Independent Director
--
--
Dr. Jonathan E Freeman, Ph.D.
Dr. Jonathan E Freeman, Ph.D.
Independent Director
Independent Director
--
--
Ms. Lisa Carson
Ms. Lisa Carson
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Robert J. Bitterman
Mr. Robert J. Bitterman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
27.15K
+168.32%
Mr. Robert L. Ferrara, CPA
Mr. Robert L. Ferrara, CPA
Lead Independent Director
Lead Independent Director
15.67K
+176.49%
Dr. Curtis A. Lockshin, Ph.D.
Dr. Curtis A. Lockshin, Ph.D.
Independent Director
Independent Director
356.00
--
Mr. David H. Deming
Mr. David H. Deming
Independent Director
Independent Director
--
--
Ms. Patricia A. (Pat) Bradford
Ms. Patricia A. (Pat) Bradford
Independent Director
Independent Director
--
--
Dr. Jonathan E Freeman, Ph.D.
Dr. Jonathan E Freeman, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Orca Capital GmbH
10.73%
Heights Capital Management, Inc.
1.90%
Macquarie Investment Management
1.04%
The Vanguard Group, Inc.
1.01%
Geode Capital Management, L.L.C.
0.87%
Other
84.45%
Accionistas
Accionistas
Proporción
Orca Capital GmbH
10.73%
Heights Capital Management, Inc.
1.90%
Macquarie Investment Management
1.04%
The Vanguard Group, Inc.
1.01%
Geode Capital Management, L.L.C.
0.87%
Other
84.45%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
15.61%
Investment Advisor/Hedge Fund
0.87%
Individual Investor
0.60%
Venture Capital
0.23%
Hedge Fund
0.05%
Research Firm
0.02%
Other
82.61%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
36
834.27K
17.39%
+508.13K
2025Q1
36
775.62K
16.17%
+505.98K
2024Q4
32
296.95K
9.15%
+222.42K
2024Q3
32
80.42K
6.72%
+23.30K
2024Q2
31
23.09K
4.32%
-37.39K
2024Q1
33
20.92K
3.89%
-41.19K
2023Q4
35
59.17K
22.55%
+23.31K
2023Q3
40
35.14K
14.50%
-1.09K
2023Q2
42
33.69K
17.19%
+22.39K
2023Q1
44
7.53K
5.91%
-5.09K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Orca Capital GmbH
514.97K
10.73%
+514.97K
--
Jan 17, 2025
Heights Capital Management, Inc.
90.99K
1.9%
+90.99K
--
Dec 31, 2024
Macquarie Investment Management
50.00K
1.04%
--
--
Apr 30, 2025
The Vanguard Group, Inc.
48.66K
1.01%
--
--
May 31, 2025
Geode Capital Management, L.L.C.
41.59K
0.87%
+41.59K
--
Mar 31, 2025
Cetera Investment Advisers LLC
38.50K
0.8%
+25.50K
+196.15%
Mar 31, 2025
Bitterman (Robert J)
10.12K
0.21%
+3.50K
+52.89%
Jun 10, 2025
Ferrara (Robert L)
5.67K
0.12%
+2.50K
+78.96%
Jun 10, 2025
Infarinato (Robert M. Esq., CPA)
11.00K
0.23%
+3.00K
+37.50%
Sep 11, 2024
XTX Markets LLC
10.80K
0.23%
+10.80K
--
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Jul 02, 2024
Merger
9<1
Jul 02, 2024
Merger
9<1
Jul 02, 2024
Merger
9<1
Jul 02, 2024
Merger
9<1
Jan 25, 2023
Merger
12<1
Jan 25, 2023
Merger
12<1
Fecha
Tipo
Relación
Jul 02, 2024
Merger
9<1
Jul 02, 2024
Merger
9<1
Jul 02, 2024
Merger
9<1
Jul 02, 2024
Merger
9<1
Jan 25, 2023
Merger
12<1
Jan 25, 2023
Merger
12<1
Jan 25, 2023
Merger
12<1
Jan 25, 2023
Merger
12<1
